ABOUT

OUR MISSION AND VISION

OUR MISSION
Neurodegenerative diseases, such as Alzheimer’s are a severe medical issue in modern societies, particularlythose with an aging population.
Despite rapid medical advances in many other fields, there has been limited development of therapeutics to treat neurogenerative diseases.
To combat this, Neuracle Science has taken a different approach to treating this spectrum of diseases.

We believe that gliosis and glial scarring are the primary biological processes that drive neurodegenerative in many diseases.
Neuracle Science is dedicated to advancing a First-In-Class therapeutic technique that exploits
novel mechanisms to regulate the glial scarring process, and ultimately, to achieve one of the most ambitious
goals in modern medicine: an effective treatment for a variety of neurodegenerative diseases.
MANAGEMENT TEAM
  • KIM, Bongcheol, Ph.D
    CEO
    View
    KIM, Bongcheol, Ph.D

    CEO

    Dr. Kim is one of our co-founders and a member of our Board of Directors. He serves as our Chief Executive Officer. He earned a B.S. in Microbiology from Seoul National University and his Ph.D in Microbiology from the University of Newcastle upon Tyne, UK.

    During his career Dr Kim has worked as a senior researcher in SK Chemicals Co. Ltd. and Pangenomics Co. Ltd. From 2009, until the founding of Neuracle Science, he served as the managing director in the Institute for Innovative Cancer Research in Asan Medical Center.

    close

  • SEONG, Jae-Young, Ph.D
    Co-founder
    Chief Scientific Advisor
    Professor of Korea University
    View
    SEONG, Jae-Young, Ph.D

    Co-founder
    Chief Scientific Advisor
    Professor of Korea University

    Dr. Seong is one of our co-founders and the scientific advisor of Neuracle Science.
    He has been a professor at Korea University College of Medicine since 2005.
    Dr. Seong is an expert in molecular biology and bioinformatics, especially in the field of GPCRs and their ligands.
    His research findings about the NGDF family are core assets of Neuracle Science.
    He earned his B.S. and Ph.D. in molecular biology from Seoul National University and his postdoctoral fellowship
    at Göttingen University before starting his career as a professor at Chonnam National University in 2000

    close

  • KIM, Songwon
    CFO
    View
    KIM, Songwon

    CFO

    Mr. Kim heads the management support group of Neuracle Science.
    He has over 20 years of experience in finance in the fields of bio-industry, venture capital, and film.
    He has developed several structures for IPO and pre-IPO funding.
    Mr. Kim earned his B.S. in business administration from Chung-Ang University.

    close

  • KIM, Wonkyum, MS
    Director
    Head of CMC group
    View
    KIM, Wonkyum, MS

    Director
    Head of CMC group

    Mr. Kim is responsible for coordinating the CMC (Chemistry, Manufacturing, and Control) affairs of Neuracle Science.
    Mr. Kim earned his M.S. in Microbiology from Seoul National University.
    He has over 18 years of experience overseeing the development and analytics of therapeutic drugs from initial
    cell lines to clinical testing in companies such as LG Life Sciences R&D Park and Hanwha Chemical R&D Center.

    close

  • LEE, Jae Keun Ph.D
    Head of R&D Center
    View
    LEE, Jae Keun Ph.D

    Head of R&D Center

    Dr. Lee heads to R&D Center as the scientific director of Neuracle Science.
    Dr. Lee is a specialist in the signaling pathways of protein kinases in the field of neurodegenerative disease.
    He earned his B.S. in chemical engineering and Ph.D. in neuroscience from Ajou University School of Medicine.
    Prior to joining Neuracle Science, he worked as a research professor at the department of life science and biotechnology of Korea University.

    close

HISTORY
  • 2015, October
    Establishment of Neuracle Science Co. Ltd.
  • 2016, May
    Secured series-A funding from QUAD Investment (3.5M USD)
  • 2016, August
    R&D grant support from the Korean Drug Development Fund (KDDF)
  • 2016, December
    Bridge funding (3M USD)
  • 2017, February
    US Patent granted on the therapeutic usage of NGDF-neutralizing antibody
  • 2017, March
    Secured Bridge funding from TIMEWISE Investment (2M USD)